| Total (n = 20) | Group H (n = 10) | Group L (n = 10) | p value (H vs L) | |
| Physical findings | ||||
| SBP (mmHg) | 138 ± 15 | 142 ± 16 | 134 ± 14 | 0.267 |
| DBP (mmHg) | 90 ± 12 | 90 ± 13 | 90 ± 13 | 0.931 |
| BMI (kg/m2) | 20.8 [16.9 - 27.4] | 25.7 ± 5.6 | 18.7 ± 3.0 | 0.004 |
| Laboratory data |
|
|
|
|
| HbA1c (%) | 5.6 [5.4 - 6.2] | 5.9 ± 0.8 | 5.6 [5.3 - 6.4] | 0.859 |
| Serum Alb (g/dL) | 4.2 ± 0.4 | 4.1 ± 0.4 | 4.3 ± 0.4 | 0.148 |
| Serum Cr (mg/dL) | 0.81 [0.73 - 1.05] | 1.10 ± 0.27 | 0.71 ± 0.05 | － |
| Serum uric acid (mg/dL) | 4.8 [3.8 - 5.7] | 5.5 ± 1.1 | 4.2 [3.1 - 4.8] | 0.026 |
| Serum potassium (mmol/L) | 4.3 ± 0.5 | 4.4 ± 0.6 | 4.3 ± 0.4 | 0.629 |
| Serum phosphorus (mg/dL) | 2.4 ± 0.8 | 1.8 [1.6 - 2.4] | 2.7 ± 0.8 | 0.173 |
| Triglyceride (mg/dL) | 105 [78 - 146] | 113 [85 - 142] | 95 [75 - 161] | 0.705 |
| HDL cholesterol (mg/dL) | 80 ± 27 | 73 ± 24 | 89 ± 29 | 0.261 |
| LDL cholesterol (mg/dL) | 113 [87 - 169] | 134 ± 43 | 111 ± 30 | 0.183 |
| Medication | ||||
| Mycophenolatemofetil | 20 (100) | 10 (100) | 10 (100) | － |
| Tacrolimus | 19 (95) | 10 (100) | 9 (90) | 0.500 |
| Cyclosporine | 1 (5) | 0 (0) | 1 (10) | 0.500 |
| Everolimus | 0 (0) | 0 (0) | 0 (0) | － |
| Steroid | 19 (95) | 10 (100) | 9 (90) | 0.500 |
| Antihypertensive agent | 10 (50) | 5 (50) | 5 (50) | 1.000 |
| Diabetes agent | 3 (15) | 2 (20) | 1 (10) | 0.500 |
| Dyslipidemia agent | 0 (0) | 0 (0) | 0 (0) | － |
| Hyperuricemia agent | 0 (0) | 0 (0) | 0 (0) | － |